Clinical Trial Update: SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the combined effects of Slo-Niacin and atorvastatin on lipoproteins and inflammatory markers in dyslipidemia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• Slo-Niacin (niacin)
• atorvastatin (atorvastatin)

Snippet

Sponsor: University of Washington | Conditions: Dyslipidemia | Phase 4 | Status: COMPLETED